Relationship between post-void residual urine volume, preoperative pyuria and intravesical recurrence after transurethral resection of bladder carcinoma.


Journal

International journal of urology : official journal of the Japanese Urological Association
ISSN: 1442-2042
Titre abrégé: Int J Urol
Pays: Australia
ID NLM: 9440237

Informations de publication

Date de publication:
Nov 2020
Historique:
received: 19 04 2020
accepted: 13 07 2020
pubmed: 3 9 2020
medline: 28 4 2021
entrez: 3 9 2020
Statut: ppublish

Résumé

To evaluate the relationship between residual urine volume, pyuria and bladder carcinoma recurrence. The clinical data of 305 patients who had post-void residual urine volume measured and preoperative pyuria were retrospectively collected. The patients were classified into three risk groups based on the presence of residual urine and pyuria: good (negative residual urine and pyuria), intermediate (positive residual urine or pyuria) and poor (positive residual urine and pyuria). Predictive factors for intravesical recurrence-free survival were statistically analyzed using Cox proportional hazard models and Kaplan-Meier methods. The propensity score matching method was used to adjust the patients' backgrounds. The median follow-up period for all patients was 44 months. The presence of residual urine (P = 0.0164) and pyuria (P = 0.0233) were two independent prognostic factors for recurrence. After patients were classified into risk groups, the poor-risk group showed significantly shorter recurrence-free survival compared with that of the good- (P = 0.0002) and intermediate-risk groups (P = 0.0090). Even after matching, the presence of residual urine was related to short recurrence-free survival in male patients (P = 0.0012). When stratified by European Organization for Research and Treatment of Cancer risk groups, the presence of pyuria was related to short recurrence-free survival, especially for intermediate-risk patients without bacillus Calmette-Guérin treatment. Post-void residual urine and preoperative pyuria are two risks for recurrence-free survival in non-muscle-invasive bladder cancer.

Identifiants

pubmed: 32875619
doi: 10.1111/iju.14352
doi:

Substances chimiques

BCG Vaccine 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1024-1030

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

© 2020 The Japanese Urological Association.

Références

Sylvester RJ, van der Meijden AP, Oosterlinck W et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur. Urol. 2006; 49: 466-77.
Kang D, Chokkalingam AP, Gridley G et al. Benign prostatic hyperplasia and subsequent risk of bladder cancer. Br. J. Cancer 2007; 96: 1475-9.
Matsumoto S, Shimizu N, Hanai T, Uemura H, Lenvin R. Bladder outlet obstruction accelerates bladder carcinogenesis. BJU Int. 2009; 103: 1436-9.
Sazuka T, Sakamoto S, Nakamura K et al. Impact of post-void residual urine volume on intravesical recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma. Int. J. Urol. 2019; 26: 1106-12.
Yamamoto S, Sakamoto S, Imamura Y et al. Intravesical irrigation on radical nephroureterectomy prevents bladder recurrence of upper urinary tract urothelial carcinoma. Int. J. Urol. 2019; 26: 791-6.
Habuchi T, Takahashi R, Yamada H, Kakehi Y, Sugiyama T, Yoshida O. Metachronous multifocal development of urothelial cancers by intraluminal seeding. Lancet 1993; 342: 1087-8.
Catto JW, Hartmann A, Stoehr R et al. Multifocal urothelial cancers with the mutator phenotype are of monoclonal origin and require panurothelial treatment for tumor clearance. J. Urol. 2006; 175: 2323-30.
Satake N, Ohno Y, Nakashima J, Ohori M, Tachibana M. Prognostic value of preoperative pyuria in patients with non-muscle invasive bladder cancer. Int. J. Urol. 2015; 22: 645-9.
Hafner C, Knuechel R, Stoehr R, Hartmann A. Clonality of multifocal urothelial carcinomas: 10 years of molecular genetic studies. Int. J. Cancer 2002; 101: 1-6.
Kim BS, Tae BS, Ku JH, Kwak C, Kim HH, Jeong CW. Rate and association of lower urinary tract infection with recurrence after transurethral resection of bladder tumor. Invest. Clin. Urol. 2018; 59: 10-7.
Asimakopoulos AD, De Nunzio C, Kocjancic E, Tubaro A, Rosier PF, Finazzi-Agrò E. Measurement of post-void residual urine. Neurourol. Urodyn. 2016; 35: 55-7.
Haylen BT, Law MG, Frazer M, Schulz S. Urine flow rates and residual urine volumes in urogynecology patients. Int. Urogynecol. J. Pelvic Floor Dysfunct. 1999; 10: 378-83.
Cameron AP, Lewicky-Gaupp C, Smith AR et al. Baseline lower urinary tract symptoms in patients enrolled in LURN: a prospective, observational cohort study. J. Urol. 2018; 199: 1023-31.
Chang SJ, Chiang IN, Hsieh CH, Lin CD, Yang SS. Age- and gender-specific nomograms for single and dual post-void residual urine in healthy children. Neurourol. Urodyn. 2013; 32: 1014-8.
Levin RM, Chichester P, Hass MA, Gosling JA, Buttyan R. Obstructive bladder dysfunction: morphological, biochemical, and molecular changes. Eur. Urol. (Suppl) 2002; 1: 14-20.
Levin R, Chichester P, Levin S, Buttyan R. Role of angiogenesis in the bladder’s response to partial outlet obstruction: a review. Scand. J. Urol. Nephrol. 2004; 38: 37-47.
Chichester P, Lieb J, Levin S, Buttyan R, Horan P, Levin RM. Vascular response of the rabbit bladder to short term partial outlet obstruction. Mol. Cell. Biochem. 2000; 208: 19-26.
Chichester P, Schröder A, Horan P, Lenvin R. Vascular response of the rabbit bladder to chronic partial outlet obstruction. Mol. Cell. Biochem. 2001; 226: 1-8.
Uhlig A, Strauss A, Seif Amir Hosseini A et al. Gender-specific differences in recurrence of non-muscle-invasive bladder cancer: a systematic review and meta-analysis. Eur. Urol. Focus 2018; 4: 924-36.

Auteurs

Tomokazu Sazuka (T)

Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan.

Shinichi Sakamoto (S)

Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan.

Yusuke Imamura (Y)

Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan.

Kazuyoshi Nakamura (K)

Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan.

Satoshi Yamamoto (S)

Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan.

Takayuki Arai (T)

Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan.

Nobuyoshi Takeuchi (N)

Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan.

Akira Komiya (A)

Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan.

Jun Teishima (J)

Department of Urology, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan.

Tomohiko Ichikawa (T)

Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH